EUVIMEDEUVIMED entdecken
Open Access

Contrasting temporal dynamics of fluorescence and photoacoustic signals from Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors

Mohammad A Saad iD, Derek Allen iD, Allison Sweeney iD, Marvin Xavierselvan iD, Srivalleesha Mallidi iD, Tayyaba Hasan iD

Science Advances · 08.05.2026 · 12 (19)

DOI: 10.1126/sciadv.adv4639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 08.05.2026. Verfasst von Mohammad A Saad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Cetuximab, Photoacoustic Techniques, ErbB Receptors, Indoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular fluorescence imaging is effective for tumor diagnosis but limited by low-depth profiling, which can be addressed by photoacoustic (PA) imaging. However, PA imaging has low sensitivity due to microenvironment-induced effects on exogenous contrast agents. Accordingly, the temporal and biophysical determinants of PA contrast in Cetuximab-IRDye800 conjugates should be performed to complement fluorescence-based diagnostics. In this study, we compare the temporal dynamics of PA and fluorescence signals from a Cetuximab-IRDye800 conjugate in a tumor xenograft model. We demonstrate that while fluorescence signal increases steadily over time after administration of Cetuximab-IRDye800, PA signal peaks early (~75% higher at 3 hours), followed by a decrease (~24% higher at 24 hours). Mechanistic analysis revealed formation of H-aggregates with Cetuximab-IRDye800 conjugation, which results in enhanced PA contrast, while receptor-mediated endocytosis disrupts these aggregates, reducing PA signal intensity over time. These findings underscore the complementary nature of PA and fluorescence imaging and emphasize timing as a critical factor for capturing peak PA contrast for tumor diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabPhotoacoustic TechniquesErbB ReceptorsIndolesOptical ImagingNeoplasmsAnimalsHumansMiceCell Line, TumorFluorescenceXenograft Model Antitumor Assays

Substanzen

CetuximabErbB ReceptorsIndolesIRDye800EGFR protein, human

Autor:innen und Institutionen

  • Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Department of Biomedical Engineering, Science and Technology Center, Tufts University, Medford, MA 02155, USA.
  • Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

ORCID-Profile: Mohammad A Saad, Derek Allen, Allison Sweeney, Marvin Xavierselvan, Srivalleesha Mallidi, Tayyaba Hasan

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Saad, M. A., Allen, D., Sweeney, A., Xavierselvan, M., Mallidi, S., & Hasan, T. (2026). Contrasting temporal dynamics of fluorescence and photoacoustic signals from Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors. Science Advances, 12(19). https://doi.org/10.1126/sciadv.adv4639

Vancouver

Saad MA, Allen D, Sweeney A, Xavierselvan M, Mallidi S, Hasan T. Contrasting temporal dynamics of fluorescence and photoacoustic signals from Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors. Science Advances. 2026;12(19). doi:10.1126/sciadv.adv4639

BibTeX
@article{Saad2026,
  author = {Saad, Mohammad A and Allen, Derek and Sweeney, Allison and Xavierselvan, Marvin and Mallidi, Srivalleesha and Hasan, Tayyaba},
  title = {Contrasting temporal dynamics of fluorescence and photoacoustic signals from Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {19},
  doi = {10.1126/sciadv.adv4639}
}
Kostenlos starten →